United States Patent 8,541,451: Scope, Claims, and Patent Landscape for Crystalline Freebase Forms III and IV
US Patent 8,541,451 claims a specific crystalline freebase of a biphenyl-2-ylcarbamic acid–based piperidine ester compound, defined by powder X-ray diffraction (PXRD) peak sets, DSC behavior, melting points, and designation as Form III or Form IV. The patent also claims pharmaceutical compositions using the crystalline forms and multi-component combinations with selected drug classes, and it includes solvent-based crystallization processes using acetonitrile with controlled addition steps and seeding.
What is the core claimed subject matter?
The patent’s claim center is the crystalline freebase structure:
-
Compound identity (same scaffold across forms):
biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester (freebase)
-
Crystalline forms claimed:
- Form III (Claim 1)
- Form IV (Claim 5)
-
Crystalline characterization required for enforceability:
The claims are not satisfied by “the same compound.” They require the powder diffraction signature and thermal behavior that match the enumerated PXRD peaks and “substantially in accordance” language tied to figures.
How narrow are the crystalline form definitions (Form III vs Form IV)?
Claim 1 scope: Form III crystalline freebase
Claim 1 requires all of:
- “Crystalline freebase” of the specified biphenyl-2-ylcarbamic acid derivative.
- PXRD peaks at 2θ values of:
- 6.6 ± 0.1
- 13.1 ± 0.1
- 18.6 ± 0.1
- 19.7 ± 0.1
- 20.2 ± 0.1
- Plus “five or more additional diffraction peaks” chosen from a listed pool of candidate 2θ values:
- 8.8, 10.1, 11.4, 11.6, 14.8, 15.2, 16.1, 16.4, 16.9, 17.5, 18.2, 19.3, 19.9, 20.8, 21.1, 21.7, 22.3 (each ± 0.1)
- Designation: “Form III”
- Melting point: “about 125°C”
This is a highly specific polymorph claim. Even if the compound is correct, infringement hinges on whether the delivered material hits the required peak set plus minimum additional peaks.
Claim 5 scope: Form IV crystalline freebase
Claim 5 requires all of:
- Same freebase identity (scaffold).
- PXRD peaks at 2θ values of:
- 6.6 ± 0.1
- 13.1 ± 0.1
- 18.6 ± 0.1
- 19.7 ± 0.1
- 20.2 ± 0.1
- Plus “five or more additional diffraction peaks” chosen from a different listed pool:
- 10.6, 15.0, 16.0, 17.3, 17.7, 20.9, 21.4, 22.6, 24.6, 27.8 (each ± 0.1)
- Designation: “Form IV”
- Melting point: “about 119°C”
Form III and IV share the same five “anchor” peaks but diverge on the additional peak set pool and on melting point. That structure usually enables enforcement via fingerprint matching rather than chemical sameness.
Side-by-side comparison: anchors vs discriminators
| Feature |
Form III (Claim 1) |
Form IV (Claim 5) |
| Required anchor PXRD peaks |
6.6, 13.1, 18.6, 19.7, 20.2 (each ±0.1) |
Same five anchors |
| “Additional peaks” |
Choose 5+ from 17-value pool (8.8 to 22.3 range) |
Choose 5+ from 10-value pool (10.6 to 27.8 range) |
| Melting point |
about 125°C |
about 119°C |
| Label |
Form III |
Form IV |
The practical consequence: a Form III material would generally fail Form IV if its additional peaks align with the Form III-leaning pool and its melting point trends toward 125°C. The reverse holds for Form IV.
How do dependent claims tighten the infringement surface?
Claims 2–4 (Form III)
- Claim 2 lists a specific set of PXRD peaks (a narrowed subset-style enumeration), requiring peaks at:
- 6.6, 11.4, 13.1, 16.1, 17.5, 18.2, 18.6, 19.3, 19.7, 19.9, 20.2, 20.8, 21.1, 21.7, 22.3 (each ±0.1)
- Claim 3: peak positions are “substantially in accordance” with FIG. 1
- Claim 4: DSC thermogram substantially in accordance with FIG. 4
Together, these claims create two routes to infringement:
- Exact peak set route (Claim 2).
- Figure-matched “substantially in accordance” route (Claims 3 and 4).
Claims 6–7 (Form IV)
- Claim 6 is analogous to Claim 3’s structure, by requiring PXRD peak pattern “substantially in accordance” with FIG. 2
- Claim 7 requires DSC thermogram “substantially in accordance” with FIG. 5
Notably, Claim 6/7 do not re-list all peak values in the text of the dependent claims, but they still tether infringement to the figure-defined PXRD/DSC outcomes.
Where does the patent broaden beyond the solid state?
Pharmaceutical composition claims: Claims 8–15
The patent adds formulation breadth in two layers: carrier-based compositions and combinations with other therapeutic agent classes.
Claim 8 (carrier + Form III)
- A pharmaceutical composition comprising:
- pharmaceutically acceptable carrier
- compound of Claim 1 (Form III)
Claim 9 (carrier + Form III + agent class)
- Claim 9 adds an “agent selected from”:
- β2 adrenergic receptor agonists
- steroidal anti-inflammatory agents
- phosphodiesterase-4 inhibitors
- combinations thereof
- It includes a logistical formulation flexibility: the crystalline form and the agent can be formulated together or separately.
Claim 10 (specific two-class combination)
- Requires β2 adrenergic receptor agonist + steroidal anti-inflammatory agent.
Claims 11 and 15 (micronized form)
- Claim 11: compound of Claim 1 in micronized form
- Claim 15: compound of Claim 5 in micronized form
“Micronized form” claims attempt to capture particle-size processing that may otherwise avoid polymorph-based arguments. The key issue for infringement is whether micronization is treated as changing physical form while retaining the claimed crystalline identity.
Claims 12–14 (carrier + Form IV, plus same agent logic)
- Claim 12 mirrors Claim 8 using compound of Claim 5
- Claim 13 mirrors Claim 9 using the Form IV crystalline compound
- Claim 14 mirrors Claim 10 using the Form IV crystalline compound
Scope impact of these composition claims
- Composition claims do not loosen the core requirement of obtaining the claimed crystalline form; they expand the use case by attaching carriers and optional co-therapies.
- The “formulated together or separately” language supports packaging strategies, including combination products and separate administration regimens.
Where is the process protection (and what can design-around target)?
Claim 16: preparation of Form III
A process for preparing crystalline freebase Form III requires:
- Contact the specified ester freebase compound with a solvent consisting of acetonitrile.
- Use a concentration ratio of ~100 mg ester per total mL acetonitrile (about 100:1).
- Add the acetonitrile in two steps.
This is a process claim with concentration and addition schedule as explicit limitations. Changing either can avoid literal infringement.
Claim 17: preparation of Form IV
Process for Form IV includes:
- a) Form seed crystal of Form III by contacting the ester with acetonitrile, at ~100:1 mg/mL, with two-step addition.
- b) Dissolve crystalline Form III in acetonitrile to form a solution.
- c) Add the seed crystal to the solution.
This claim is enforceable against process implementations that:
- intentionally generate Form III seed,
- dissolve that Form III in acetonitrile,
- and then induce Form IV growth by seeding.
How does the claim structure affect freedom-to-operate (FTO)?
Solid state: polymorph fingerprinting is the gate
Because Claim 1 and Claim 5 define the crystalline forms through PXRD peak patterns and melting points, an FTO analysis must treat the crystalline form as a product-by-process-limited polymorph rather than a generic chemical.
Practical infringement likelihood tracks:
- PXRD peak presence at required anchor values
- ability to satisfy “five or more additional peaks” within the permitted pool
- melting point alignment (about 125°C vs about 119°C)
- figure-matching for dependent claims where applicable
Composition: co-therapy does not remove the polymorph requirement
Even if competitors use the correct active agent combination classes (β2 agonist and steroid or PDE4 inhibitor), they still need to use the claimed crystalline form to fall within composition claims.
Process: parameter changes are the primary design-around lever
Acetonitrile-only solvent restriction and the 100:1 ratio plus two-step addition and seeding are explicit. Process developers can target:
- solvent identity not limited to acetonitrile,
- ratio outside “about 100:1,”
- non-two-step addition,
- or crystallization routes that do not involve Form III seeding for Form IV.
Patent landscape map: what this patent typically covers relative to neighboring filings
Given the claim scope, US 8,541,451 sits in a common crystalline-drug patent family pattern:
- core invention: specific crystalline polymorphs (Form III and Form IV)
- enforceability mechanism: PXRD/DSC-defined polymorph identity
- business coverage: API as crystalline form, plus composition claims with carrier and co-therapies, plus micronized variants
- manufacturing coverage: acetonitrile crystallization processes including controlled addition and seeding
In that landscape, the most relevant competitive risk is the use of:
- the same polymorph(s) (Form III / Form IV),
- the same or closely related crystallization conditions using acetonitrile,
- micronized material that still meets the polymorph criteria.
Key Takeaways
- US 8,541,451 is a polymorph-focused patent covering two crystalline freebase forms of a specific biphenyl-2-ylcarbamic acid piperidine ester scaffold: Form III (mp ~125°C) and Form IV (mp ~119°C).
- Infringement for Forms III and IV depends on PXRD fingerprint requirements: shared anchor peaks (6.6, 13.1, 18.6, 19.7, 20.2 ±0.1) plus minimum additional peaks from defined pools.
- The patent broadens to pharmaceutical compositions with pharmaceutically acceptable carriers and combinations with β2 adrenergic receptor agonists, steroidal anti-inflammatory agents, and phosphodiesterase-4 inhibitors, with “together or separately” formulation latitude.
- The patent also claims micronized forms of both crystalline forms and includes process claims tied to acetonitrile with a ~100:1 concentration, two-step addition (Form III), and Form III seeding (Form IV).
FAQs
1) Does this patent cover the freebase compound without specifying the crystalline form?
No. The core independent claims require the material to be the crystalline freebase and to meet PXRD peak and melting point criteria tied to Form III or Form IV.
2) What are the “anchor” PXRD peaks for both Form III and Form IV?
Both require PXRD diffraction peaks at 2θ = 6.6 ± 0.1, 13.1 ± 0.1, 18.6 ± 0.1, 19.7 ± 0.1, and 20.2 ± 0.1.
3) How do Form III and Form IV differ if they share the same anchor peaks?
They differ in the allowed set/pool of additional diffraction peaks and in melting point (about 125°C for Form III vs about 119°C for Form IV), plus dependent claims tie to specific figure-matched patterns/DSC.
4) Do the composition claims allow formulation strategies that avoid combining agents in one unit?
Yes. Claim 9 and Claim 13 state the crystalline form and the agent can be formulated together or separately.
5) What process parameters are explicitly limited in the crystallization claims?
For Form III, the process requires acetonitrile-only solvent, a ~100 mg ester per mL acetonitrile ratio (about 100:1), and two-step acetonitrile addition. For Form IV, it requires Form III seeding into an acetonitrile solution after dissolving Form III.
References
[1] United States Patent 8,541,451, claims 1-17 (as provided in the prompt).
